Analysts have said that the recent decline in headline inflation can be attributed to naira stability and a reduction in ...

The S&P/ASX 200 Index (ASX: XJO) held onto its gains, and then some, following February’s unemployment figures. Here’s why.

Shares rise, new job creation undercuts forecasts; Morgan Stanley downgrades NAB; Nanosonics rallies; Fed sees “transitory” ...

Discover 9 companies poised for Dividend King status! Explore diverse sectors, growth rates, yields & insights on challenges ...

Treatment involved an antithrombin-based dose regimen targeting antithrombin levels between 15% and 35%, starting at 50 mg ...

Opportunities in quality U.S. value stocks continue to emerge. Read about three selections with dividends and potential ...

Tom Lee managing partner and head of research at Fundstrat Global Advisors appeared on a CNBC interview to talk about how the ...

We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a ...

US medical giants say Australia’s Pharmaceutical Benefits Scheme is an “egregious and discriminatory” program that Trump ...

Esperion plans to begin two phase III studies on bempedoic acid alone and in combination with ezetimibe in pediatric patients with familial hypercholesterolemia.

German drugmaker Grünenthal pushed its latest opioid as a safer option. People around the world got hooked. Madlen Davies, Hristio Boytchev, and Rafael Cabrera report.